Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3458]

ASCO 2020: Maintenance therapy With PARP inhibitor olaparib extends survival by over 1 year in patients with relapsed ovarian cancer and BRCA mutation

ASCO 2020: Maintenance therapy With PARP inhibitor olaparib extends survival by over 1 year in patients with...

Study confirms one-week radiotherapy schedule is safe and effective following breast cancer surgery – a major benefit to patients and over-stretched health services

Study confirms one-week radiotherapy schedule is safe and effective following breast cancer surgery – a major...

Cervical cancer screening during the COVID-19 Crisis: Africa view point

Cervical cancer screening during the COVID-19 Crisis: Africa view point

FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions

FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions

FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers

FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal...

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer

Approval of targeted therapies first line for prostate cancer ‘will ease Covid-19 pressures’

Approval of targeted therapies first line for prostate cancer ‘will ease Covid-19 pressures’

Cancer patients face high mortality from COVID-19

Cancer patients face high mortality from COVID-19

FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma

FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma

Innovative approach offers option for treating upper tract urothelial cancer

Innovative approach offers option for treating upper tract urothelial cancer

More from ecancer